In combination with known Lck peptides for HLA-A2+ or -A24+ cancer patients (Harashima et al, 2001; Imai et al, 2001), those identified in the present study enable us to develop a peptide-based anti-cancer vaccine for cancer patients with metastases in diverse ethnic populations. The gene discussed is LCK; the disease is cancer.